secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001193125-22-275058
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Biosciences appoints Chris Williams as COO, effective Oct. 31, 2022
-------------------------------------------------------------------------

- Chris Williams appointed COO, reporting to CEO Wenbin Jiang; focused on scaling global operations.
- Annual base salary of $395,000; target bonus 50% of base; $100,000 sign-on cash bonus (clawback within 12 months).
- Equity grants of $500,000, split 50% stock options and 50% RSUs, vesting over four years.
- Williams previously VP at Thermo Fisher Scientific and Bayer Pharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312522275058/0001193125-22-275058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312522275058/d405062d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-275058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer